AZD4512

AZD4512 is an antibody-drug conjugate (ADC) that targets CD22, a protein expressed on the surface of B cells. It is under investigation as a treatment for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), including Philadelphia chromosome positive (Ph[+]) and negative (Ph[–]) subtypes, as well as for patients with measurable residual disease after failing or relapsing following standard therapies. AZD4512 is being evaluated as both monotherapy and in combination with other anticancer agents in a Phase I/II clinical trial. Its mechanism of action involves binding to CD22 on malignant B cells, leading to cell death via delivery of the cytotoxic payload linked to the antibody. The drug is developed by AstraZeneca[1][3][5].